BridgeMD
The usage of unenriched emulsified fat transplant in temporomandibular joint degenerative diseases
EU CTIS ID: 2024-520244-41-00
What this study is testing
The aim of this study is to determine the effectiveness of using nanofat in the treatment of temporomandibular joint osteoarthritis (TMJ OA). The study seeks to identify correlations between the patient's subjective symptoms, clinical presentation, and radiological findings, perform data analysis, and apply the results in clinical practice. The hypothesis of this study is that the injection of autologous nanofat into the temporomandibular joint slows the progression of degenerative changes, promotes the regeneration of the deformed joint surface, and thereby improves the quality of life for patients.
- Therapeutic exploratory (Phase II)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- The study plans to include patients aged 18-65 years, with TMJ OA classified as stage 4 or 5 according to the Wilkes classification (9), and who have not responded to at least 6 months of conservative treatment. Participation in the study is voluntary, and the participant may withdraw at any stage.
You likely can't join if
- Exclusion criteria include pregnancy, severe chronic diseases (malignant tumors, lymphoproliferative disorders, coagulation disorders, diabetes, acute viral infections, and severe general health conditions), or prior surgical treatment of the temporomandibular joint.
The study team makes the final eligibility decision.
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18-64 years. The study team makes the final eligibility decision.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.